

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Medlive Technology Co., Ltd.

醫脈通科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2192)

VOLUNTARY ANNOUNCEMENT

ON-MARKET SHARE REPURCHASE UNDER THE GENERAL MANDATE

This is a voluntary announcement made by the board of directors (the “**Board**”) of Medlive Technology Co., Ltd. (the “**Company**”).

On 26 October 2026, the Company has commenced the repurchase of its own shares (“**Shares**”) on the open market. The Share repurchases were conducted in accordance with the general mandate to repurchase Shares granted by the shareholders of the Company at the annual general meeting held on 15 May 2026 (the “**Repurchase Mandate**”) and were funded with the Company’s internal resources.

The Company is of the view that the current share price level of the Company does not fully reflect its long-term value. Based on the assessment of the Company’s long-term development prospects and the prudent consideration of the interests of shareholders, the Company will prudently and orderly conduct on-market Share repurchase arrangements within the scope of the Repurchase Mandate, subject to compliance with applicable laws, regulations and regulatory requirements.

Pursuant to the Repurchase Mandate, the Board hereby announces that it intends to continue repurchasing shares on the open market within the limits of the Repurchase Mandate, strictly in compliance with all applicable laws and regulations, including the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). Furthermore, no repurchases will be conducted if as a result, any shareholder of the Company is obliged to make a general offer for all the Shares under The Codes on Takeovers and Mergers and Share Buy-backs. All repurchases will be funded by the Company’s internal resources and the repurchased Shares will be held by the Company as treasury Shares. The exact timing, price range and implementation pace of the repurchases will be prudently determined by the Board having regard to market conditions and the Company’s capital structure management needs.

The Board considers that the implementation of repurchases at the current valuation level is in the overall interests of the Company and its shareholders.

Shareholders and investors should note that any Share repurchase will be conducted at the discretion of the Board having regard to market conditions, Share price level and the Company's capital structure management requirements. The Company does not guarantee the timing, volume or price of any Share repurchase. Shareholders and potential investors should therefore exercise caution when dealing in the securities of the Company.

By order of the Board
Medlive Technology Co., Ltd.
Tian Liping
Chairwoman and Chief Executive Officer

Hong Kong, 26 October 2026

As at the date of this announcement, the Board comprises Ms. Tian Liping, Mr. Tian Lixin, Mr. Tian Lijun and Ms. Zhou Xin as executive Directors; Mr. Eiji Tsuchiya and Mr. Kazutaka Kanairo as non-executive Directors; and Mr. Richard Yeh, Dr. Ma Jun and Ms. Wang Shan as independent non-executive Directors.